产品
编 号：F760986
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 872514-65-3
产品详情
生物活性：
Rilotumumab (AMG 102) is an anti-HGF (anti-hepatocyte growth factor) monoclonal antibody, inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research.
体内研究：
Rilotumumab (intraperitoneal injection; 1.5 mg/kg; once two days; 11 d) treatment inhibits glioma cell growth in vivo.Animal Model:6-8-week-old BALB/c nu/nu female mice subcutaneous injected with U87MG.vIII cells
Dosage:1.5 mg/kg
Administration:Intraperitoneal injection; 1.5 mg/kg; once two days; 11 days
Result:Reduced U87MG.vIII xenograft growth (P=0.0002) compared with vehicle-treated xenografts (P=0.0001).
体外研究：
Rilotumumab (10 μg/mL; overnight) shows the decrease of MET phosphorylation at Y1234 and Y1235, and an increase in total MET.
Rilotumumab (AMG 102) is an anti-HGF (anti-hepatocyte growth factor) monoclonal antibody, inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research.
体内研究：
Rilotumumab (intraperitoneal injection; 1.5 mg/kg; once two days; 11 d) treatment inhibits glioma cell growth in vivo.Animal Model:6-8-week-old BALB/c nu/nu female mice subcutaneous injected with U87MG.vIII cells
Dosage:1.5 mg/kg
Administration:Intraperitoneal injection; 1.5 mg/kg; once two days; 11 days
Result:Reduced U87MG.vIII xenograft growth (P=0.0002) compared with vehicle-treated xenografts (P=0.0001).
体外研究：
Rilotumumab (10 μg/mL; overnight) shows the decrease of MET phosphorylation at Y1234 and Y1235, and an increase in total MET.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备